Acerta Pharma LLC
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$79.7M
Doctors Paid
1,061
Transactions
4,228
2024 Total
$3.1M
Payment Breakdown by Category
Research$77.1M (96.7%)
Consulting$2.3M (2.9%)
Food & Beverage$51,211 (0.1%)
Travel$30,903 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $77.1M | 2,621 | 96.7% |
| Consulting Fee | $2.3M | 351 | 2.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $219,083 | 43 | 0.3% |
| Food and Beverage | $51,211 | 1,106 | 0.1% |
| Grant | $50,000 | 1 | 0.1% |
| Travel and Lodging | $30,903 | 59 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $12,400 | 4 | 0.0% |
| Education | $1,730 | 43 | 0.0% |
Payments by Type
Research
$77.1M
2,621 transactions
General
$2.7M
1,607 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | $13.4M | 24 | 449 |
| A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma | $10.0M | 0 | 742 |
| A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia | $9.4M | 2 | 249 |
| Part 1 FL An Open label Phase 1b Study of ACP196 Alone or in Combination with Rituximab in Subjects with Follicular Lymphoma Part 2 MZL An Open label Phase 1b or 2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent Bcell Non Hodgkin Lymphoma | $7.7M | 0 | 157 |
| A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation | $7.7M | 0 | 194 |
| A Phase Ib Study of ACP196 in combination with Obinutuzumab for Patients with Untreated CLL or SLL or PLL | $4.4M | 0 | 11 |
| A Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma | $4.0M | 0 | 65 |
| This study is a multicenter open label nonrandomized sequential group dose escalation study to assess safety tolerability pharmacokinetics and preliminary anti tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies | $3.7M | 0 | 69 |
| A Proof of Concept Study of the Combination of ACP196 and Pembrolizumab in Subjects with Hematologic Malignancies | $2.6M | 0 | 61 |
| A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | $1.9M | 0 | 107 |
| A Proof of Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed or Refractory BCell Malignancies | $1.8M | 0 | 44 |
| A Phase 1 Multicenter Open label and Dose escalation Study of ACP196 in Subjects with Chronic Lymphocytic Leukemia Richters Syndrome or Prolymphocytic Leukemia | $1.7M | 0 | 52 |
| A Phase 2 Proof of Concept Study of the Combination of ACP196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma | $1.1M | 0 | 50 |
| Randomized Phase 2 Trial of ACP196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma RAPID CHECK study | $1.1M | 0 | 16 |
| An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenstrom Macroglobulinemia | $1.1M | 0 | 47 |
| An Open label Phase 2 Study of ACP 196 Acalabrutinib in Subjects With Mantle Cell Lymphoma | $844,578 | 0 | 19 |
| A Proof of Concept Study of the Combination of ACP196 and ACP319 in Subjects with Bcell Malignancies | $616,530 | 0 | 34 |
| A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | $615,205 | 2 | 37 |
| A Phase II Study of acalabrutinib, venetoclax and obinutuzumab (AVO) for CLL | $535,601 | 0 | 3 |
| A Phase 2 Proof of Concept Study of the Combination of ACP196 and Pembrolizumab in Subjects with Advanced Non small Cell Lung Carcinoma | $395,930 | 0 | 45 |
| A Phase 2 Proof of Concept Study of ACP 196 Alone and in Combination with Pembrolizumab in Subjects with Recurrent Ovarian Cancer | $325,425 | 0 | 31 |
| A Multicenter Open label Study of ACP196 in Subjects with Recurrent Glioblastoma Multiforme | $313,049 | 0 | 11 |
| A Phase 1b 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Hematologic Malignancies | $252,315 | 0 | 1 |
| A Phase 2 Proof of Concept Study of the Combination of ACP196 and Pembrolizumab in Subjects with Advanced Ovarian Cancer | $179,693 | 0 | 29 |
| Immunomodulatory BTK-i and PI3Kd-i to potentiate in situ vaccine and immunotransplant for lymphoma | $130,000 | 0 | 1 |
| Pharmacokinetic analysis and translational studies examining the contribution of CD49d to the development of | $103,500 | 0 | 1 |
| An Open label Phase 1b Study of ACP196 in Subjects with Relapsed or Refractory de Novo Activated B-cell ABC Subtype of Diffuse Large BCell Lymphoma | $75,078 | 0 | 5 |
| A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects with Relapsed or Refractory Mantle Cell Lymphoma or other B-cell Malignancies | $73,100 | 0 | 8 |
| Prospective, Interventional Pilot Study of Mobile Devices and Digital Applications to Detect Early Pneumonitis and Other Pulmonary Adverse Events in Unresectable Stage III Non-Small Cell Lung Cancer Patients on Durvalumab | $62,443 | 0 | 18 |
| a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia | $57,357 | 0 | 14 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology & Oncology | $1.5M | 54 | $28,275 |
| Hematology | $586,140 | 12 | $48,845 |
| Diagnostic Radiology | $108,568 | 6 | $18,095 |
| Obstetrics & Gynecology | $50,629 | 3 | $16,876 |
| Internal Medicine | $43,746 | 144 | $303.79 |
| Allergy & Immunology | $43,662 | 89 | $490.58 |
| Medical Oncology | $36,824 | 10 | $3,682 |
| Pediatric Hematology-Oncology | $28,320 | 1 | $28,320 |
| Pulmonary Disease | $21,486 | 71 | $302.62 |
| Allergy | $13,157 | 29 | $453.69 |
| Family | $8,789 | 140 | $62.78 |
| Critical Care Medicine | $8,446 | 39 | $216.56 |
| Pediatric Allergy/Immunology | $8,111 | 6 | $1,352 |
| Family Medicine | $5,598 | 63 | $88.86 |
| Physician Assistant | $4,883 | 73 | $66.89 |
| Pediatrics | $3,790 | 30 | $126.35 |
| Student in an Organized Health Care Education/Training Program | $3,784 | 11 | $343.98 |
| Nurse Practitioner | $2,967 | 46 | $64.51 |
| Specialist | $2,593 | 7 | $370.43 |
| Medical | $1,618 | 29 | $55.80 |
| Adult Health | $1,424 | 21 | $67.79 |
| Acute Care | $1,147 | 15 | $76.45 |
| Registered Nurse | $881.69 | 18 | $48.98 |
| Anatomic Pathology & Clinical Pathology | $689.28 | 6 | $114.88 |
| Cardiovascular Disease | $624.03 | 9 | $69.34 |
| Endocrinology, Diabetes & Metabolism | $432.09 | 16 | $27.01 |
| General Practice | $429.24 | 11 | $39.02 |
| Nephrology | $365.22 | 12 | $30.44 |
| Gastroenterology | $316.05 | 2 | $158.03 |
| Rheumatology | $246.64 | 11 | $22.42 |
| Sleep Medicine | $211.19 | 6 | $35.20 |
| Interventional Cardiology | $190.00 | 6 | $31.67 |
| Hospitalist | $158.98 | 5 | $31.80 |
| Psychiatric/Mental Health | $154.46 | 2 | $77.23 |
| Surgical | $138.29 | 2 | $69.15 |
| Gynecology | $129.99 | 1 | $129.99 |
| Pediatric Emergency Medicine | $129.99 | 1 | $129.99 |
| Infectious Disease | $125.49 | 2 | $62.75 |
| Neonatal-Perinatal Medicine | $125.00 | 1 | $125.00 |
| Otolaryngology | $122.47 | 4 | $30.62 |
| Perinatal | $121.59 | 1 | $121.59 |
| Emergency Medicine | $118.98 | 2 | $59.49 |
| Surgery | $108.17 | 1 | $108.17 |
| Women's Health | $108.17 | 1 | $108.17 |
| Dermatopathology | $106.94 | 1 | $106.94 |
| Adult Medicine | $100.45 | 1 | $100.45 |
| Gerontology | $80.75 | 3 | $26.92 |
| Psychiatric/Mental Health, Adult | $77.23 | 1 | $77.23 |
| Neurological Surgery | $75.00 | 1 | $75.00 |
| Primary Care | $65.37 | 4 | $16.34 |
| Pediatric Pulmonology | $55.74 | 3 | $18.58 |
| Optometrist | $55.31 | 1 | $55.31 |
| Radiation Oncology | $40.12 | 2 | $20.06 |
| Facial Plastic Surgery | $39.28 | 2 | $19.64 |
| Adolescent Medicine | $31.57 | 2 | $15.79 |
| Obstetrics | $23.88 | 1 | $23.88 |
| Geriatric Medicine | $22.66 | 1 | $22.66 |
| Infusion Therapy | $19.26 | 1 | $19.26 |
| Sports Medicine | $17.27 | 1 | $17.27 |
| Neurology | $14.00 | 1 | $14.00 |
| Vascular Surgery | $13.29 | 1 | $13.29 |
| Neuromusculoskeletal Medicine & OMM | $12.93 | 1 | $12.93 |
Top Paid Doctors — Page 39
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Spencer Matthews | Student in an Organized Health Care Education/Training Program | Florence, SC | $12.74 | $0 |
| Dr. Stephanie Strickland, Md, MD | Family Medicine | Florence, SC | $12.74 | $0 |
| Mrs. Morgan Armstrong, Pa-C, PA-C | Physician Assistant | West Columbia, SC | $12.74 | $0 |
| Kimberly Hartzell, M.d, M.D | Pediatric Pulmonology | Melbourne, FL | $12.74 | $0 |
| Heather Shelton, Md, MD | Family Medicine | Florence, SC | $12.74 | $0 |
| Manuel Bloom, M.d, M.D | Pulmonary Disease | Houston, TX | $12.71 | $0 |
| Kenneth Lloyd, M.d, M.D | Internal Medicine | Houston, TX | $12.71 | $0 |
| Mr. Aaron Fausett, Pa, PA | Physician Assistant | Salem, UT | $12.69 | $0 |
| Dr. Warren Austin, Md, MD | Internal Medicine | Va Beach, VA | $12.65 | $0 |
| Dr. Karen Mcgeehan, M.d, M.D | Family Medicine | Virginia Beach, VA | $12.65 | $0 |
| Elizabeth Barea, Pa, PA | Medical | Va Beach, VA | $12.65 | $0 |
| Keith Paull, M.d, M.D | Allergy & Immunology | College Station, TX | $12.62 | $0 |
| Dr. William Palmer, M.d, M.D | Family Medicine | Jonesboro, AR | $12.59 | $0 |
| Mrs. Dale Barwick, Anp, ANP | Adult Health | Summerton, SC | $12.58 | $0 |
| Dr. Christopher Mahr, Md, MD | Family Medicine | Sumter, SC | $12.58 | $0 |
| Mrs. Lymaris Garcia-Medina, Md, MD | Pulmonary Disease | Hudson, NY | $12.57 | $0 |
| Dr. Samuel Jacobson, Md, MD | Pulmonary Disease | Chattanooga, TN | $12.56 | $0 |
| Yune-Gill Jeong, Md, MD | Pulmonary Disease | Chattanooga, TN | $12.56 | $0 |
| Dalitza Alvarez Valentin, M.d, M.D | General Practice | San Juan, PR | $12.51 | $0 |
| Dr. Lisa Strahm, M.d, M.D | Endocrinology, Diabetes & Metabolism | San Diego, CA | $12.48 | $0 |
| Katie Riegle, Pa-C, PA-C | Physician Assistant | Pensacola, FL | $12.41 | $0 |
| Erica George-Saintilus, Md, MD | Family Medicine | Fort Walton Beach, FL | $12.41 | $0 |
| Silvia Huebner, M.d, M.D | Internal Medicine | Springfield, MO | $12.35 | $0 |
| Michael Plastow, P.a, P.A | Physician Assistant | Springfield, MO | $12.35 | $0 |
| David Renner, Pa-C, PA-C | Physician Assistant | Springfield, MO | $12.35 | $0 |
Ad
Top Products
- CALQUENCE $74.8M
- IMFINZI $76,385
Payment Categories
- Food & Beverage $51,211
- Consulting $2.3M
- Travel & Lodging $30,903
- Research $77.1M
About Acerta Pharma LLC
Acerta Pharma LLC has made $79.7M in payments to 1,061 healthcare providers, recorded across 4,228 transactions in the CMS Open Payments database. In 2024, the company paid $3.1M. The top product by payment volume is CALQUENCE ($74.8M).
Payments were distributed across 62 medical specialties. The top specialty by payment amount is Hematology & Oncology ($1.5M to 54 doctors).
Payment categories include: Food & Beverage ($51,211), Consulting ($2.3M), Research ($77.1M), Travel & Lodging ($30,903).